Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam

Arch Gen Psychiatry. 1989 Apr;46(4):326-32. doi: 10.1001/archpsyc.1989.01810040032006.

Abstract

Healthy adult volunteers (n = 52) received single oral doses of flurazepam hydrochloride (15 mg), temazepam (15 mg), triazolam (0.25 mg), or placebo in a parallel, double-blind study. Sedative effects were greatest with triazolam, followed next by temazepam; peak effects closely coincided with peak plasma concentrations. Differential recovery from sedation corresponded in part to differences in mean elimination halflife, although sedative effects returned to baseline before plasma drug concentrations became undetectable. Sedation following flurazepam administration was less intense than with triazolam and temazepam. When tested at three hours after dosing, none of the active treatments impaired learning of a 16-item word list. However, at 24 hours, triazolam recipients could not recall a significant fraction of what was learned. Thus, dynamic differences among three benzodiazepine hypnotics may be partly explained by kinetic differences, as well as, we should caution, by possible "clinical inequivalence" in dosage.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-Anxiety Agents / pharmacokinetics*
  • Double-Blind Method
  • Female
  • Flurazepam / blood
  • Flurazepam / pharmacokinetics*
  • Half-Life
  • Humans
  • Learning / drug effects
  • Male
  • Memory / drug effects
  • Middle Aged
  • Placebos
  • Sleep / drug effects
  • Temazepam / blood
  • Temazepam / pharmacokinetics*
  • Therapeutic Equivalency
  • Triazolam / blood
  • Triazolam / pharmacokinetics*

Substances

  • Anti-Anxiety Agents
  • Placebos
  • Triazolam
  • Temazepam
  • Flurazepam